Memorial Sloan Kettering Cancer Center | Strategic Alliance Partners

A discussion on the use of circulating tumor DNA (ctDNA) as a prognostic biomarker in HR+/HER2- breast cancer.

The expert panel reviews data updates on neoadjuvant therapy in HR+/HR2- early breast cancer and discusses the role of CDK4/6 inhibition in this setting.

Experts on HR+/HER2- breast cancer discuss unmet needs in the early-stage setting.

A panel of expert oncologists review standard-of-care treatment approaches for HR+/HER2- early breast cancer and genetic testing practices when utilizing PARP inhibitors.

Eileen M. O'Reilly, MD, discusses survival outcomes from the phase 3 NAPOLI 3 trial in patients with metastatic pancreatic ductal adenocarcinoma.

Helena A. Yu, MD, discusses findings from a phase 1 trial investigating the bispecific antibody-drug conjugate BL-B01D1, which is directed against both HER3 and EGFR, in patients with locally advanced or metastatic solid tumors such as non–small cell lung cancer and small cell lung cancer.

Ezra Rosen, MD, PhD, discusses the investigation of the triplet combination of zotatifin, abemaciclib, and fulvestrant in a phase 1/2 trial in heavily pretreated patients with estrogen receptor-positive metastatic breast cancer.

The first-line combination of lenvatinib and pembrolizumab elicited durable responses with a manageable safety profile in patients with non–clear cell renal cell carcinoma, according to findings from the phase 2 KEYNOTE-B61 trial.

Bob T. Li, MD, PhD, MPH, discusses the results of a phase 1/2 study of the first-in-class immune-stimulating antibody conjugate BDC-1001 in patients with advanced HER2-expressing solid tumors.

The triplet combination of zotatifin, abemaciclib, and fulvestrant demonstrated a confirmed overall response rate of 21% in heavily pretreated patients with estrogen receptor–positive metastatic breast cancer.

Treatment with the IDH1/2 inhibitor vorasidenib reduced the risk of progression or death by 61% compared with placebo for patients with grade 2 IDH-mutant glioma, according to findings from the phase 3, double-blind INDIGO trial.

Neoadjuvant treatment with fluorouracil, leucovorin, and oxaliplatin proved to be as effective as pelvic chemoradiation with fewer adverse effects in patients with locally advanced rectal cancer who were eligible for sphincter-sparing surgery.

Liposomal irinotecan plus 5-fluorouracil/leucovorin and oxaliplatin generated statistically significant and clinically meaningful overall survival and progression-free survival benefits compared with gemcitabine plus nab-paclitaxel in treatment-naïve patients with metastatic pancreatic ductal adenocarcinoma.

Andrew Katims, MD, MPH, discusses the feasibility of using single-cell RNA-sequencing in FGFR3-mutated upper tract urothelial carcinoma

Andrew Katims, MD, MPH, discusses the rationale for investigating immune responses in the tumor microenvironment of FGFR3-mutated upper tract urothelial carcinoma using single-cell RNA-sequencing.

Andrew Katims, MD, MPH, discusses research characterizing immune responses in the tumor microenvironment of FGFR3-mutated upper tract urothelial carcinoma using single-cell RNA-sequencing

For the 11th consecutive year, OncLive is honored to recognize oncology leaders whose innovations have contributed to immeasurable improvements in outcomes for countless patients.

Adjuvant treatment with the individualized RNA neoantigen vaccine autogene cevumeran in combination with atezolizumab and chemotherapy induced notable T-cell activity that could be correlated with delayed recurrence in patients with pancreatic ductal adenocarcinoma.

Yonina R. Murciano-Goroff, MD, MSc, DPhil, discusses the evaluation of LY3537982 in patients with KRAS G12C–mutated non–small cell lung cancer, colorectal cancer, and other solid tumors.

Yonina R. Murciano-Goroff, MD, MSc, DPhil, discusses the investigation of the novel KRAS G12C inhibitor LY3537982 in patients with non–small cell lung cancer, colorectal cancer, and other solid tumors.

Komal Jhaveri, MD, FACP, discusses findings from the dose-escalation portion of the first-in-human phase 1 ReDiscover trial (NCT05216432) of the PI3Kα inhibitor RLY-2608 in patients with PIK3CA-mutant advanced breast cancer.

The combination of batiraxcept and cabozantinib is safe and generated early evidence of efficacy in pretreated patients with advanced or metastatic clear cell renal cell carcinoma.

The RAF dimer inhibitor BGB-3245 generated early efficacy signals with a tolerable safety profile in patients with advanced or refractory solid tumors harboring MAPK pathway mutations.

Patients with African ancestry with colorectal cancer have fewer actionable gene mutations than those with European ancestry, leading to fewer targeted treatment options in this population.

Despite a high-profile clinical disappointment, the TIGIT immune checkpoint remains an important target for anticancer therapy, with research programs testing novel agents moving forward in non–small cell lung cancer and a range of other tumor types.

Micheal Foote, MD, discusses the use of tucatinib plus trastuzumab compared with chemotherapy in the management of HER2-amplified metastatic colorectal cancer.

Zachary Epstein-Peterson, MD, discusses the use of CAR T-cell therapy in mantle cell lymphoma and highlights questions that remain to be answered within the treatment landscape.

Zachary Epstein-Peterson, MD, discusses available treatment approaches for patients with mantle cell lymphoma who are transplant eligible or ineligible.

Ryan Kahn, MD, MHS, discusses the investigation of Newcastle disease virus encoded with interleukin 12 in ovarian cancer.

Beryl Manning-Geist, MD, discusses findings from a study evaluating the effects of primary treatment modality on secondary cytoreduction outcomes in patients with high-grade ovarian cancer.